Oxford BioMedica PLC - Asset Resilience Ratio
Oxford BioMedica PLC (OXB) has an Asset Resilience Ratio of 0.01% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Oxford BioMedica PLC's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2022)
This chart shows how Oxford BioMedica PLC's Asset Resilience Ratio has changed over time. See Oxford BioMedica PLC balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Oxford BioMedica PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Oxford BioMedica PLC market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX31.00K | 0.01% |
| Total Liquid Assets | GBX31.00K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Oxford BioMedica PLC maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Oxford BioMedica PLC Industry Peers by Asset Resilience Ratio
Compare Oxford BioMedica PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871 |
Biotechnology | 6.52% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Annual Asset Resilience Ratio for Oxford BioMedica PLC (2003–2022)
The table below shows the annual Asset Resilience Ratio data for Oxford BioMedica PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.00% | GBX23.00K ≈ $2.80 |
GBX460.18 Million ≈ $55.99K |
-0.03pp |
| 2021-12-31 | 0.03% | GBX74.00K ≈ $9.00 |
GBX237.23 Million ≈ $28.86K |
-0.10pp |
| 2020-12-31 | 0.13% | GBX239.00K ≈ $29.08 |
GBX183.93 Million ≈ $22.38K |
-2.08pp |
| 2019-12-31 | 2.21% | GBX2.72 Million ≈ $330.82 |
GBX122.93 Million ≈ $14.96K |
-18.69pp |
| 2012-12-31 | 20.90% | GBX5.11 Million ≈ $621.13 |
GBX24.42 Million ≈ $2.97K |
-7.84pp |
| 2011-12-31 | 28.74% | GBX7.50 Million ≈ $912.53 |
GBX26.09 Million ≈ $3.18K |
+6.89pp |
| 2010-12-31 | 21.85% | GBX5.60 Million ≈ $681.72 |
GBX25.64 Million ≈ $3.12K |
-20.25pp |
| 2009-12-31 | 42.09% | GBX18.50 Million ≈ $2.25K |
GBX43.95 Million ≈ $5.35K |
+10.21pp |
| 2008-12-31 | 31.89% | GBX13.75 Million ≈ $1.67K |
GBX43.12 Million ≈ $5.25K |
-12.56pp |
| 2007-12-31 | 44.45% | GBX27.18 Million ≈ $3.31K |
GBX61.16 Million ≈ $7.44K |
-13.24pp |
| 2006-12-31 | 57.68% | GBX20.50 Million ≈ $2.49K |
GBX35.54 Million ≈ $4.32K |
+9.96pp |
| 2005-12-31 | 47.72% | GBX23.50 Million ≈ $2.86K |
GBX49.24 Million ≈ $5.99K |
-13.50pp |
| 2004-12-31 | 61.22% | GBX17.50 Million ≈ $2.13K |
GBX28.58 Million ≈ $3.48K |
-25.12pp |
| 2003-12-31 | 86.34% | GBX31.70 Million ≈ $3.86K |
GBX36.71 Million ≈ $4.47K |
-- |
About Oxford BioMedica PLC
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The… Read more